CoChat

Altering Chemosensitivity by Modulating Translation Elongation

Open access
Robert, Francis, Carrier, Marilyn, Rawe, Svea, Chen, Samuel, Lowe, Scott, Pelletier, Jerry · 2009 · PLoS ONE

The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The process of translation occurs at a nexus point downstream of a number of signal pathways and developmental processes. Modeling activation of the PTEN/AKT/mTOR pathway in the Emu-Myc mouse is a valuable tool to study tumor genotype/chemosensitivity relationships in vivo. In this model, blocking translation initiation with silvestrol, an inhibitor of the ribosome recruitment step has been showed to modulate the sensitivity of the tumors to the effect of standard chemotherapy. However, inhibitors of translation elongation have been tested as potential anti-cancer therapeutic agents in vitro, but have not been extensively tested in genetically well-defined mouse tumor models or for potential synergy with standard of care agents. METHODOLOGY/PRINCIPAL FINDINGS: Here, we chose four structurally different chemical inhibitors of translation elongation: homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Emu-myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2, or eIF4E. We show that in some genetic settings, translation elongation inhibitors are able to synergize with doxorubicin by reinstating an apoptotic program in tumor cells. We attribute this effect to a reduction in levels of pro-oncogenic or pro-survival proteins having short half-lives, like Mcl-1, cyclin D1 or c-Myc. Using lymphomas cells grown ex vivo we reproduced the synergy observed in mice between chemotherapy and elongation inhibition and show that this is reversed by blocking protein degradation with a proteasome inhibitor. CONCLUSION/SIGNIFICANCE: Our results indicate that depleting short-lived pro-survival factors by inhibiting their synthesis could achieve a therapeutic response in tumors harboring PTEN/AKT/mTOR pathway mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0005428

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Translation elongation inhibitors alter the chemosensitivity of Pten+/−Eμ-Myc lymphomas. A. Schematic diagram illustrating the chemical structure of elongation inhibitors used in this study. B. Kaplan-Meier curves representing the time to relapse following treatment of mice bearing Pten+−Eμ-Myc tumors. Ten animals were treated in each cohort. All mice were treated at the same time and in the same experiment, but the data is presented as two curves for ease of visualization. P<0.001 for significance among all curves of combination treatments compared to single agent treatments, as determined by the log rank test. C. Translation elongation inhibitors potentiate the apoptotic program induced by Dxr in Pten+/−Eμ-Myc lymphomas in vivo. Representative micrographs of Pten+/−Eμ-Myc lymphomas following treatments (original magnification, ×200). Mice were first treated with elongation inhibitors or Rap and injected again 24 hrs later with the same compounds with or without combination treatment with Dxr. Four hours later, tumors were extracted and processed for TUNEL analysis. The percentage of cells that stained positive is indicated at the top right and represents the average of three different fields where 500 cells were counted per field. This experiment was repeated three times with similar results. D. Representative Western blot analysis of Pten+/−Eμ-Myc lymphomas treated as described in (C). Tumor cells were extracted, lysed, and the levels of cleaved-PARP (c-PARP) and α-tubulin determined by Western blotting. This experiment was performed on three independent tumor samples with similar results.
Figure 1 Translation elongation inhibitors alter the chemosensitivity of Pten+/−Eμ-Myc lymphomas. A. Schematic diagram illustrating the chemical structure of elongation inhibitors used in this study. B. Kaplan-Meier curves representing the time to relapse following treatment of mice bearing Pten+−Eμ-Myc tumors. Ten animals were treated in each cohort. All mice were treated at the same time and in the same experiment, but the data is presented as two curves for ease of visualization. P<0.001 for significance among all curves of combination treatments compared to single agent treatments, as determined by the log rank test. C. Translation elongation inhibitors potentiate the apoptotic program induced by Dxr in Pten+/−Eμ-Myc lymphomas in vivo. Representative micrographs of Pten+/−Eμ-Myc lymphomas following treatments (original magnification, ×200). Mice were first treated with elongation inhibitors or Rap and injected again 24 hrs later with the same compounds with or without combination treatment with Dxr. Four hours later, tumors were extracted and processed for TUNEL analysis. The percentage of cells that stained positive is indicated at the top right and represents the average of three different fields where 500 cells were counted per field. This experiment was repeated three times with similar results. D. Representative Western blot analysis of Pten+/−Eμ-Myc lymphomas treated as described in (C). Tumor cells were extracted, lysed, and the levels of cleaved-PARP (c-PARP) and α-tubulin determined by Western blotting. This experiment was performed on three independent tumor samples with similar results.CC BY · PubMed Central
Figure 2 Translation elongation inhibitors alter the chemosensitivity of Eμ-Myc/eIF4E lymphomas. A. Kaplan-Meier curves representing the time to relapse following treatment of mice bearing Eμ-Myc/eIF4E tumors. Ten animals were treated in each cohort. All mice were treated at the same time and in the same experiment, but the data is presented as two curves for ease of visualization. P<0.001 for significance among all curves of combination treatments involving Bru+Dxr, HHT+Dxr, Did+Dxr, and CHX+Dxr compared to single agent treatments, as determined by the log rank test. B. Eμ-Myc/Bcl-2 tumors are highly resistant to the combination of translation elongation inhibition and Dxr in vivo. Kaplan-Meier plot showing tumor-free survival of mice (n = 10 for each cohort) bearing Eμ-Myc/Bcl-2 tumors following treatment. Log rank analysis of the curves of combination relative to single agent treatments shows a significant difference between Dxr and Rap+Dxr, HHT+Dxr, Did+Dxr and Bru+Dxr, but not CHX+Dxr with P-values of 0.003, 0.002, 0.004, 0.003 and 0.120, respectively. C. Western blot analysis of Eμ-Myc/Bcl-2 lymphomas treated as indicated above the panel. Tumor cells were extracted, lysed, and the levels of cleaved-PARP (c-PARP) and α-tubulin determined by Western blotting. The Western blots were performed on two independent tumor samples with similar results.
Figure 2 Translation elongation inhibitors alter the chemosensitivity of Eμ-Myc/eIF4E lymphomas. A. Kaplan-Meier curves representing the time to relapse following treatment of mice bearing Eμ-Myc/eIF4E tumors. Ten animals were treated in each cohort. All mice were treated at the same time and in the same experiment, but the data is presented as two curves for ease of visualization. P<0.001 for significance among all curves of combination treatments involving Bru+Dxr, HHT+Dxr, Did+Dxr, and CHX+Dxr compared to single agent treatments, as determined by the log rank test. B. Eμ-Myc/Bcl-2 tumors are highly resistant to the combination of translation elongation inhibition and Dxr in vivo. Kaplan-Meier plot showing tumor-free survival of mice (n = 10 for each cohort) bearing Eμ-Myc/Bcl-2 tumors following treatment. Log rank analysis of the curves of combination relative to single agent treatments shows a significant difference between Dxr and Rap+Dxr, HHT+Dxr, Did+Dxr and Bru+Dxr, but not CHX+Dxr with P-values of 0.003, 0.002, 0.004, 0.003 and 0.120, respectively. C. Western blot analysis of Eμ-Myc/Bcl-2 lymphomas treated as indicated above the panel. Tumor cells were extracted, lysed, and the levels of cleaved-PARP (c-PARP) and α-tubulin determined by Western blotting. The Western blots were performed on two independent tumor samples with similar results.CC BY · PubMed Central
Figure 3 Inhibition of translation elongation in mice bearing Pten+/−Eμ-Myc lymphomas leads to reduced amounts of Mcl-1, Cyclin D1, and c-Myc. Mice bearing Pten+/−Eμ-Myc tumors were treated for 28 hrs (two injections; 24 hrs apart) with either Rap (4 mg/kg), HHT (0.25 mg/kg), Bru (0.5 mg/kg), Did B (0.05 mg/kg) or CHX (12.5 mg/kg). A. At 28 hrs (lanes 2–6) tumor cells were extracted, lysed, and proteins fractionated by SDS-PAGE followed by Western blot analysis. The vehicle control mice were treated like the 28 hrs compound treatments except that compounds were omitted. B. Assessment of mRNA levels in Pten+/−Eμ-Myc tumors by qRT-PCR. The change in mRNA amounts relative to vehicle-treated controls (V) from three independent experiments is shown as a bar graph with standard deviation. Quantitation of the data from three independent experiments performed as in A is also superimposed on these graphs.
Figure 3 Inhibition of translation elongation in mice bearing Pten+/−Eμ-Myc lymphomas leads to reduced amounts of Mcl-1, Cyclin D1, and c-Myc. Mice bearing Pten+/−Eμ-Myc tumors were treated for 28 hrs (two injections; 24 hrs apart) with either Rap (4 mg/kg), HHT (0.25 mg/kg), Bru (0.5 mg/kg), Did B (0.05 mg/kg) or CHX (12.5 mg/kg). A. At 28 hrs (lanes 2–6) tumor cells were extracted, lysed, and proteins fractionated by SDS-PAGE followed by Western blot analysis. The vehicle control mice were treated like the 28 hrs compound treatments except that compounds were omitted. B. Assessment of mRNA levels in Pten+/−Eμ-Myc tumors by qRT-PCR. The change in mRNA amounts relative to vehicle-treated controls (V) from three independent experiments is shown as a bar graph with standard deviation. Quantitation of the data from three independent experiments performed as in A is also superimposed on these graphs.CC BY · PubMed Central
Figure 4 A. HHT and Bru inhibit polysome formation in Pten+/−Eμ-Myc tumors. Mice bearing well-palpable Pten+/−Eμ-Myc tumors were treated with either vehicle (DMSO), HHT (0.25 mg/kg), or Bru (0.5 mg/kg). Two hours later, tumors were harvested and cell extracts prepared and fractionated through 10%–50% sucrose gradients. Polyribosomes were monitored by measuring the OD260 using an ISCO UA-6 UV detector. The experiment was repeated two more times with similar results.
Figure 4 A. HHT and Bru inhibit polysome formation in Pten+/−Eμ-Myc tumors. Mice bearing well-palpable Pten+/−Eμ-Myc tumors were treated with either vehicle (DMSO), HHT (0.25 mg/kg), or Bru (0.5 mg/kg). Two hours later, tumors were harvested and cell extracts prepared and fractionated through 10%–50% sucrose gradients. Polyribosomes were monitored by measuring the OD260 using an ISCO UA-6 UV detector. The experiment was repeated two more times with similar results.CC BY · PubMed Central
Figure 5 Treatment of mice with HHT and Bru inhibits general protein synthesis in vivo. Pten+/−Eμ-Myc tumors were isolated from HHT− or Bru- treated animals and their polyribosomes fractionated on 10–50% sucrose gradients. RNA was purified from the indicated fractions and quantified using qRT-PCR for Mcl-1, cyclin D1, c-Myc and β-actin levels. The amount of mRNA in each fraction was determined relative to vehicle-treated mice. The values are averaged from three independent experiments and the error bars denote the error of mean (n = 3).
Figure 5 Treatment of mice with HHT and Bru inhibits general protein synthesis in vivo. Pten+/−Eμ-Myc tumors were isolated from HHT− or Bru- treated animals and their polyribosomes fractionated on 10–50% sucrose gradients. RNA was purified from the indicated fractions and quantified using qRT-PCR for Mcl-1, cyclin D1, c-Myc and β-actin levels. The amount of mRNA in each fraction was determined relative to vehicle-treated mice. The values are averaged from three independent experiments and the error bars denote the error of mean (n = 3).CC BY · PubMed Central
Figure 6 MG132 antagonizes the effects of elongation inhibitors on the levels of Mcl-1, Cyclin D1, and c-Myc. Tsc2+/−Eμ-Myc lymphomas were pre-treated with MG132 (lanes 5–8) or vehicle (lanes 1–4) for 30 min and exposed to HHT (100 nM) (A), Did B (100 nM) (B), Bru (100 nM) (C) or CHX (1 µM) (D) for the indicated periods of time (lanes 1–8). At the end of each incubation, the cells were harvested, lysed and the levels of Mcl-1, cyclin D1, c-Myc and β-actin determined by Western blotting. The right panel of each gel shows the intensities of each band relative to the 0 hr control with standard deviation from three independent experiments.
Figure 6 MG132 antagonizes the effects of elongation inhibitors on the levels of Mcl-1, Cyclin D1, and c-Myc. Tsc2+/−Eμ-Myc lymphomas were pre-treated with MG132 (lanes 5–8) or vehicle (lanes 1–4) for 30 min and exposed to HHT (100 nM) (A), Did B (100 nM) (B), Bru (100 nM) (C) or CHX (1 µM) (D) for the indicated periods of time (lanes 1–8). At the end of each incubation, the cells were harvested, lysed and the levels of Mcl-1, cyclin D1, c-Myc and β-actin determined by Western blotting. The right panel of each gel shows the intensities of each band relative to the 0 hr control with standard deviation from three independent experiments.CC BY · PubMed Central
Figure 7 MG132 antagonizes the toxicity of HHT and Rap on Tsc2+/−Eμ-Myc lymphomas and interferes with their Dxr-associated synergism. A. Cells were exposed to the indicated concentrations of HHT or Rap in the presence or absence of 10 µM MG132. Cell viability was determined 16 hrs later. The results are presented as the fraction of viable cells relative to vehicle (0.02% DMSO) treated samples with the standard deviation presented (n = 3). B. Lymphomas cells were treated with increasing concentrations and HHT and Dxr or Rap and Dxr at a fixed ratio in presence or absence of a fixed MG132 concentration (10 µM) for 16 hrs and the cell viability was determined. A CI value below 1 indicates a synergistic effect whereas a value above 1 represents antagonism. These experiments were performed three times with similar results.
Figure 7 MG132 antagonizes the toxicity of HHT and Rap on Tsc2+/−Eμ-Myc lymphomas and interferes with their Dxr-associated synergism. A. Cells were exposed to the indicated concentrations of HHT or Rap in the presence or absence of 10 µM MG132. Cell viability was determined 16 hrs later. The results are presented as the fraction of viable cells relative to vehicle (0.02% DMSO) treated samples with the standard deviation presented (n = 3). B. Lymphomas cells were treated with increasing concentrations and HHT and Dxr or Rap and Dxr at a fixed ratio in presence or absence of a fixed MG132 concentration (10 µM) for 16 hrs and the cell viability was determined. A CI value below 1 indicates a synergistic effect whereas a value above 1 represents antagonism. These experiments were performed three times with similar results.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 2

  1. H-G Wendel, 2004, Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy., Nature, 428, 332, 10.1038/nature02369 · DOI · Paper page
  2. JR Mills, 2008, mTORC1 promotes survival through translational control of Mcl-1., Proc Natl Acad Sci U S A, 105, 10853, 10.1073/pnas.0804821105 · DOI · Paper page

Cited by

See all 91

Metadata

Authors
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J.
Affiliations
  • McGill University (CA)
  • Howard Hughes Medical Institute (US)
Corresponding author
Pelletier, Jerry
Venue
PLoS ONE
Published
2009-05-01
Volume
4
Issue
5
Pages
e5428
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2012346470
Cited by
90
References
67
Citations by year
2026: 5 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 8 · 2013: 13 · 2012: 12
FWCI
4.16
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Canadian Institutes of Health Research (79385_1)
  • National Cancer Institute (P30CA008748)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
chemosensitivity, chemoresistance, Eμ-Myc lymphoma, homoharringtonine, bruceantin, didemnin B, cycloheximide, doxorubicin synergy, apoptosis, Mcl-1, cyclin D1, c-Myc, eIF4E, TSC2, proteasome inhibition, ribosome recruitment
MeSH terms
Tuberous Sclerosis Complex 2 Protein, Homoharringtonine, Animals, Base Sequence, Cycloheximide, Female, Harringtonines, Lymphoma, Mice, Inbred C57BL, Mutation, Peptide Chain Elongation, Translational, Genes, myc, Proto-Oncogene Proteins c-myc, DNA Primers, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Genes, bcl-2, Cyclin D1, Tumor Suppressor Proteins, Quassins, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Depsipeptides, PTEN Phosphohydrolase, Mice, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Altering Chemosensitivity by Modulating Translation Elongation. https://app.cochat.ai/papers/10.1371/journal.pone.0005428
The paper
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009). Altering Chemosensitivity by Modulating Translation Elongation. PLoS ONE. https://doi.org/10.1371/journal.pone.0005428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.